Abstract
Heterobimetallic compounds are designed to harness chemotherapeutic traits of distinct metal species into a single molecule. The ruthenium–gold (Ru–Au) family of compounds based on Au–N-heterocyclic carbene (NHC) fragments [Cl2(p-cymene)Ru(μ-dppm)Au(NHC)]ClO4 was conceived to combine the known antiproliferative and cytotoxic properties of Au–NHC-based compounds and the antimigratory, antimetastatic, and antiangiogenic characteristic of specific Ru-based compounds. Following recent studies of the anticancer efficacies of these Ru–Au–NHC complexes with promising potential as chemotherapeutics against colorectal, and renal cancers in vitro, we report here on the mechanism of a selected compound, [Cl2(p-cymene)Ru(μ-dppm)Au(IMes)]ClO4 (RANCE-1, 1). The studies were carried out in vitro using a human clear cell renal carcinoma cell line (Caki-1). These studies indicate that bimetallic compound RANCE-1 (1) is significantly more cytotoxic than the Ru (2) or Au (3) monometallic derivatives. RANCE-1 significantly inhibits migration, invasion, and angiogenesis, which are essential for metastasis. RANCE-1 was found to disturb pericellular proteolysis by inhibiting cathepsins, and the metalloproteases MMP and ADAM which play key roles in the etiopathogenesis of cancer. RANCE-1 also inhibits the mitochondrial protein TrxR that is often overexpressed in cancer cells and facilitates apoptosis evasion. We found that while auranofin perturbed migration and invasion to similar degrees as RANCE-1 (1) in Caki-1 renal cancer cells, RANCE-1 (1) inhibited antiangiogenic formation and VEGF expression. We found that auranofin and RANCE-1 (1) have distinct proteolytic profiles. In summary, RANCE-1 constitutes a very promising candidate for further preclinical evaluations in renal cancer.
Graphical Abstract

This is a preview of subscription content, access via your institution.








Abbreviations
- ANCE-1:
-
[AuCl(IMes)]
- ATCC:
-
American Type Culture Collection
- ADAM:
-
A disintegrin and metalloproteinase
- Auranofin:
-
[(2R,3R,4S,5R,6S)-3,4,5-Tris(acetyloxy)-6-{[(triethyl-λ5-phosphanylidene)aurio]sulfanyl}oxan-2-yl]methyl acetate
- Caki-1:
-
Human clear cell renal cell carcinoma
- Cisplatin:
-
Cis-diamminedichloroplatinum(II)
- dppm:
-
Diphenylphosphanylmethyl(diphenyl)phosphane
- DTNB:
-
3,3′-Disulfanediylbis(6-nitrobenzoic acid)
- HCT 116:
-
Human colorectal carcinoma
- HUVEC:
-
Human umbilical vein endothelial cells
- ILs:
-
Interleukins
- IMes:
-
1,3-Bis(2,4,6-trimethylphenyl)imidazol-2-ylidene
- IRM90:
-
Human foetal lung fibroblast
- MMPs:
-
Matrix metalloproteinase
- NHC:
-
N-Heterocyclic carbene
- p-cymene:
-
4-Isopropyltoluene
- R:
-
[Ru(p-Cymene)Cl2(dppm-κP)]
- RANCE-1:
-
[Cl2(p-Cymene)Ru(μ-dppm)Au(IMes)]ClO4
- TNB2− :
-
5-Thio-2-nitrobenzoic acid
- TrRx:
-
Thioredoxin reductase
- VEGF:
-
Vascular endothelial growth factor
References
Pelletier F, Comte V, Massard A, Wenzel M, Toulot S, Richard P, Picquet M, Le Gendre P, Zava O, Edafe F, Casini A, Dyson PJ (2010) J Med Chem 53:6923–6933
Liu Y, Chen TF, Wong Y-S, Mei W-J, Huang X-M, Yang F, Liu J, Zheng W-J (2010) Chem-Biol Interact 183:349–356
Wenzel M, Bertrand B, Eymin M-J, Comte V, Harvey JA, Richard P, Groessl M, Zava O, Amrouche H, Harvey PD, Le Gendre P, Picquet M, Casini A (2011) Inorg Chem 50:9472–9480
Bjelosevic H, Guzei IA, Spencer LC, Persson T, Kriel FH, Hewer R, Nell MJ, Gut J, van Resburg CEJ, Rosenthal P, Coates J, Darkwa J, Elmroth SKC (2102) J Organomet Chem 720:52–59
Kaushik NK, Mishra A, Ali A, Adhikari JS, Verma AK, Gupta R (2012) J Inorg Biol Chem 17:1217–1230
Nieto D, Gonzalez-Vadillo AM, Bruna S, Pastor CJ, Rios-Luci C, Leon LG, Padron JM, Navarro-Ranninger C, Cuadrado I (2012) Dalton Trans 41:432–441
Lease N, Vasileviski V, Carreira M, de Almeida A, Sanaú M, Hirva P, Casini A, Contel M (2013) J Med Chem 56:5806–5818
Garcia-Moreno E, Gascon S, Rodriguez-Yoldi MJ, Cerrada E, Laguna M (2013) Organometallics 32:3710–3720
Barreiro E, Casas JS, Couce MD, Sanchez A, Sordo J, Vazquez-Lopez EM (2104) J Inorg Biochem 131:68–75
Wenzel M, Bigaeva E, Richard P, Le Gendre P, Picquet M, Casini A, Bodio E (2014) J Inorg Biochem 141:10–16
Fernandez-Moreira V, Marzo I, Gimeno C (2014) Chem Sci 5:4434–4446
Zaidi Y, Arjmand F, Zaidi N, Usmani JA, Zubair H, Akhatar K, Hossain M, Shadab GGHA (2014) Metallomics 6:1469–1479
Govender P, Lemmerhirt H, Hutton AT, Therrien B, Bednarski PJ, Smith GS (2014) Organometallics 33:5535–5545
Bertrand B, Citta A, Franken IL, Picquet M, Folda A, Scalcon V, Rigobello MP, Le Gendre P, Casini A, Bodio E (2015) J Biol Inorg Chem 20:1005–1020
Boselli L, Carraz M, Mazeres S, Paloque L, Gonzalez G, Benoit-Vical F, Valentin A, Hemmert C, Gornitzka H (2015) Organometallics 34:1046–1055
Nieto D, Bruna S, Gonzalez-Vadillo AM, Perles J, Carrillo-Hermosilla F, Antiniolo A, Padron JM, Plata GB, Cuadrado I (2015) Organometallics 34:5407–5417
Nithyakumar A, Alexander V (2015) Dalton Trans 44:17800–17809
Fenton JB, Busse M, Rendina LM (2015) Aus J Chem 68:576–580
Ma L, Ma R, Wang Z, Yiu S-M, Zhu G (2016) Chem Commun 52:10735–10738
Singh N, Jang S, Jo J-H, Kim DH, Park DW, Kim I, Kim H, Kang SC, Chi K-W (2016) Chemistry-A Eur J 22:16157–16164
Lopes J, Alves D, Morais TS, Costa PJ, Piedade M, Fatima M, Marques F, Villa de Brito MJ, Garcia MH (2017) J Inorg Biochem 169:68–78
Luengo A, Fernandez-Moreira V, Marzo I, Gimeno MC (2017) Inorg Chem 56:15159–15170
González-Pantoja JF, Stern M, Jarzecki AA, Royo E, Robles-Escajeda E, Varela-Ramirez A, Aguilera RJ, Contel M (2011) Inorg Chem 50:11099–11110
Fernández-Gallardo J, Elie BT, Sulzmaier F, Sanaú M, Ramos JW, Contel M (2014) Organometallics 33:6669–6681
Fernández-Gallardo J, Elie BT, Sadhukha T, Prabha S, Sanaú M, Rotenberg SA, Ramos JW, Contel M (2015) Chem Sci 6: 5269-5283. (b) Contel M, Fernández-Gallardo J, Elie BT, Ramos JW. US Patent 9,315,531 (04/19/2016)
Mui YF, Fernández-Gallardo J, Gubran A, Elie BT, Maluenda I, Sanaú M, Navarro O, Contel M (2016) Organometallics 35:1218–1227
Massai L, Fernández-Gallardo J, Guerri A, Arcangeli A, Pillozzi S, Contel M, Messori L (2015) Dalton Trans 44:11067–11076
Fernández-Gallardo J, Elie BT, Sanaú M, Contel M (2016) Chem Commun 52:3155–3158
Dean TC, Yang M, Liu M, Grayson JM, DeMartino AW, Day CS, Lee J, Furdui CM, Bierbach U (2017) ACS Med Chem Lett 8:572–576
Das S, Sinha S, Britto R, Somasundaram K, Samuelson AG (2010) J Inorg Biochem 104:93–104
Fremont P, Scott NM, Stevens ED, Nolan SP (2005) Organometallics 24:2411–2418
Varghese E, Busselberg D (2014) Cancers 6:2243–2258 and refs therein
Roder C, Thomson MJ (2015) Drugs R D 15:13–20
Adhireksan Z, Davey GE, Campomanes P, Groessl M, Clavel CM, Yu H, Nazarov AA, Yeo CHF, Ang WH, Droge P, Rothlisberger U, Dyson PJ, Davey CA (2014) Nature Comm 5:3462
Nakayaa A, Sagawa M, Muto A, Uchida H, Ikedaa Y, Kizari M (2011) Leukemia Res 35:243–249
Liu C, Liu Z, Li M, Li X, Wong Y-S, Ngai S-M, Zheng W, Zhang Y, Chen T (2013) PLoS ONE 8:e53945
Fan C, Zheng W, Fu X, Li X, Wong Y-S, Chen T (2014) Cell Death and Disease 5:e191
Park S-H, Lee JH, Berek JS, Hu MC-T (2014) Int J Oncol 45:1691–1698
Denkert C, Furstenberg A, Daniel PT, Koch I, Kobell M, Weichert W, Siegert A, Hauptmann S (2013) Oncogene 22:8653–8661
Moutasim KA, Nystrom ML, Thomas GJ (2011) Methods Mol Biol 731:333–343
Hulkower KI, Herber RL (2011) Pharmaceutics 3:107–124
DeCicco-Skinner KL, Henry GH, Cataisson C, Tabib T, Gwilliam JC, Watson NJ, Bullwinkle EM, Falkenburg L, O’Neill RC, Morin A, Wiest JS (2014) J Vis Exp 91:e51312
Cheng X, Holenya P, Can S, Alborzinia H, Rubbiani R, Ott I, Wölfl S (2014) Mol Cancer 13:221
Farina AR, Tacconelli A, Cappabianca L, Masciulli MP, Holmgren A, Beckett GJ, Gulino A, Mackay AR (2001) Eur J Biochem 268:405–413
Lim HV, Hong S, Jin W, Lim S, Kim SJ, Kang HJ, Park EH, Ahn K, Lim CJ (2005) Exp Mol Med 37:497–506
Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello AP (2007) Free Radic Biol Med 42:872–881
Zou M, Zhang X, Xu C (2016) Cell Oncol 39:47–57
Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, Hsieh CY (2003) Oncogene 22:1517–1527
Suzuki M, Tetsuka T, Yoshida S, Watanabe N, Kobayashi M, Matsui N, Okamoto T (2000) FEBS Lett 465:23–27
Quail DF, Joyce JA (2013) Nat Med 19:1423–1437
Kwong W-L, Lam K-Y, Lok C-N, Lai Y-T, Lee P-Y, Che C-M (2016) Angew Chem Int Ed 55:13524–13528
Lippitz BE, Harris RA (2016) Oncoimmunology 11(5):e1093722
Welte T, Zhang XH (2015) Mediators Inflamm 2015:804347. https://doi.org/10.1155/2015/804347
Kim N-M, Lee M-Y, Park S-J, Choi J-S, Oh M-K (2007) Kim In-S. Immunology 122:607–614
Li Q, Chen B, Cai J, Sun Y, Wang G, Li Y, Li R, Feng Y, Han B, Li J, Tian Y, Yi L, Jiang C (2016) PLoS ONE 11:e0151815
Overall CM, Kleifeld O (2006) Nat Rev Cancer 6:227–239
He ZH, Chen N, Wang D, Bin Y, She JX (2014) Eur J Pharmacol 740:240–247
Woo JH, Lim JH, Kim YH, Suh SI, Min DS, Chang JS, Lee YH, Park JW, Kwon TK (2004) Oncogene 23:1845–1853
Woessner JF, Nagase H (2000) Matrix metalloproteinases and TIMPs: protein profile. Oxford University Press, Oxford
Rocks N, Paulissen G, El Hour M, Quesada F, Crahay C, Gueders M, Foidart JM, Noel A, Cataldo D (2008) Biochimie 90:369–379
Schlomann U, Koller G, Conrad C, Ferdous T, Golfi P, Garcia AM, Höfling S, Parsons M, Costa P, Soper R, Bossard M, Hagemann T, Roshani R, Sewald N, Ketchem RR, Moss ML, Rasmussen FH, Miller MA, Lauffenburger DA, Tuveson DA, Nimsky C, Bartsch JW (2015) Nat Commun 6:6175
Yousef EM, Tahir MR, St-Pierre Y, Gaboury LA (2014) BMC Cancer 14:609
Olson OC, Joyce JA (2015) Nat Rev Cancer 15:712–729
Sevenich L, Joyce JA (2014) Genes Dev 28:2331–2347
Bakst RL, Xiong H, Chen CH, Deborde S, Lyubchik A, Zhou Y, He S, McNamara W, Lee SY, Olson OC, Leiner IM, Marcadis AR, Keith JW, Al-Ahmadie HA, Katabi N, Gil Z, Vakiani E, Joyce JA, Pamer E, Wong RJ (2017) Cancer Res 22:6400–6414
Casini A, Gabbiani C, Sorrentino F, Rigobello MP, Bindoli A, Geldbach TJ, Marrone A, Re N, Hartinger CG, Dyson PJ, Messori L (2008) J Med Chem 51:6773–6781
Acknowledgements
We thank the National Cancer Institute (NCI) for grant 1SC1CA182844 (M.C.) and Dr. Karen Hubbard for providing infrastructure and advice. We are grateful to Dr. Natalia Curado and Yu-Fung Mui for their assistance in the preparation of the metallic compounds, Mike A. Cornejo for his assistance with some IC50 assays, and Ciara Bagnall for her technical expertise in imaging and immunocytochemistry.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Elie, B.T., Pechenyy, Y., Uddin, F. et al. A heterometallic ruthenium–gold complex displays antiproliferative, antimigratory, and antiangiogenic properties and inhibits metastasis and angiogenesis-associated proteases in renal cancer. J Biol Inorg Chem 23, 399–411 (2018). https://doi.org/10.1007/s00775-018-1546-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00775-018-1546-8
Keywords
- Bimetallic
- Ruthenium–gold
- Renal cancer
- Mechanisms
- Auranofin